Cytokinetics:接受阿菲卡坦治疗的患者中51%在NYHA功能分级上有一个或多个等级改善,而接受美托洛尔治疗的患者仅为26%

美股速递
Aug 30

Cytokinetics:接受阿菲卡坦治疗的患者中51%在NYHA功能分级上有一个或多个等级改善,而接受美托洛尔治疗的患者仅为26%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10